Clarifying the role of rasburicase in tumor lysis syndrome

Pharmacotherapy

Volumn 27, Issue 1, 2007, Pages 111-121

  Sood, Amy R ^a   Burry, Lisa D ^b   Cheng, Doret K F ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Hyperuricemia; Rasburicase; Tumor lysis syndrome

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; RASBURICASE; URIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE CLASSIFICATION; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG LABELING; DYSPNEA; EDEMA; FEVER; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEADACHE; HEALTH CARE COST; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; HYDRATION; HYPERURICEMIA; HYPOXIA; INCIDENCE; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; METHEMOGLOBINEMIA; MORTALITY; MULTICENTER STUDY; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; SYNDROME DELINEATION; TACHYCARDIA; TACHYPNEA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL; URTICARIA; VOMITING; WHEEZING;

ALLOPURINOL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; GOUT SUPPRESSANTS; HUMANS; NEOPLASMS; TUMOR LYSIS SYNDROME; URATE OXIDASE;

EID: 33846085073     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.1.111     Document Type: Review

References (34)

1. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber M. Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004;116:546-54.
2. Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother 2003;37:1047-54.
3. Cairo MS, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification. Br J Haematol 2004;127:3-11.
4. Navolanic PM, Pui CH, Larson RA, et al. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a meeting report, Dallas, Texas, January 2002. Leukemia 2003;17:499-514.
5. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993;94:133-9.
6. Annemans L, Moeremans K, Lamotte M, et al. Incidence, medical resource utilization and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma 2003;44:77-83.
7. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors: a case report and review of the literature. Cancer Chemother Pharmacol 2003;51:187-92.
8. Andreoli SP, Clark JH, McGuire WA, et al. Purine excretion during tumor lysis in children with acute lymphocytic leukemia receiving allopurinol: relationship to acute renal failure. J Pediatr 1986;109:292-8.
9. van den Berg H, Reintsema AM. Renal tubular damage in rasburicase: risks of alkalinisation. Ann Oncol 2004;15:175-6.
10. Sanofi-Synthelabo. Elitek (rasburicase) product monograph. New York, NY; 2005. Available from http://products.sanofi-aventis.us/elitek/elitek. html. Accessed June 25, 2006.
11. Sanofi-Synthelabo Canada Inc. Fasturtec (rasburicase) product monograph. Markham, Ontario, Canada; 2003.
12. McEvoy, GK, ed. Allopurinol. In: American hospital formulary service (AHFS) drug information 2006. Bethesda, MD: American Society of Health-System Pharmacists, 2006.
13. Gutierrez-Macias A, Lizarralde-Palacios E, Martinex-Odriozola P, Miguel-De la Villa F. Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia. BMJ 2005;331:623-4.
14. Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother 2005;39:1932-5.
15. Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998-3003.
16. Lascombes F, Sommelet D, Gebhard F, et al. High efficacy of recombinant urate oxidase in prevention of renal failure related to tumor lysis syndrome (TLS) [abstr]. Blood 1998;92:237b.
17. Pui C, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol 2001;19: 697-704.
18. Pui CH, Jeha S, Irwin D, et al. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. Leukemia 2001;15:1505-9.
19. Coiffer B, Mounier N, Bologna S, et al. Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (groupe d'etude des lymphomes de l'adulte trial on rasburicase activity in adult lymphoma) study. J Clin Oncol 2003;21: 4402-6.
20. Bosly A, Sonet A, Pinkerton CR, et al. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study. Cancer 2003;98: 1048-54.
21. Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005;19:34-8.
22. Wang L, Shih L, Chang H, et al. Recombinant urate oxidase (rasburicase) for the prevention and treatment of tumor lysis syndrome in patients with hematologic malignancies. Acta Haematol 2006;115:35-8.
23. Shin HY, Kang HJ, Park ES, et al. Recombinant urate oxidase (rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: results of a compassionate prospective multicenter study in Korea. Pediatr Blood Cancer 2006;46:439-45.
24. Mahmoud HH, Leverger G, Patte C, et al. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer 1998;77(suppl 4):18-20.
25. Lee ACW, Chak H, So KT, Chan R. Treatment of impending tumor lysis with single-dose rasburicase. Ann Pharmacother 2003;37:1614-17.
26. Hummel M. Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome. Leukemia 2003;17:2542-4.
27. Delman BS, Reuter JP, Arnold T, Feemster AA, Shanholtz CB. Development of and adherence to established guidelines for rasburicase in an academic medical center. Presented at the 39th American Society of Health-System Pharmacists midyear clinical meeting and exhibits, Orlando, FL, December 5-9, 2004.
28. Arnold TM, Reuter JP, Delman BS, et al. Use of a single-dose rasburicase in an obese female. Ann Pharmacother 2004;38:1428-31.
29. Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 2005;29:463-5.
30. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy 2006;26:242-7.
31. Trifilio S, Gordon L, Singhal S, et al. Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006;37:997-1001.
32. McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006;26:806-12.
33. Bell T, Candrilli S, Irish W, et al. Medical resource use and costs associated with renal complications among patients with hematologic malignancies [abstr]. Blood 2002;100:221a.
34. Annemans L, Moeremans K, Lamotte M, et al. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients. Support Care Cancer 2003;11:249-57.